![]() |
市场调查报告书
商品编码
1722826
2025 年至 2033 年药物传递市场规模、份额、趋势及预测(按给药途径、应用、最终用户和地区)Pharmaceutical Drug Delivery Market Size, Share, Trends, and Forecast by Route of Administration, Application, End User, and Region, 2025-2033 |
2024 年全球药物输送市场规模价值为 14,652 亿美元。展望未来, IMARC Group估计到 2033 年市场规模将达到 22,055 亿美元,2025-2033 年期间的复合年增长率为 4.6%。北美目前占据市场主导地位,到 2024 年将占据 42.6% 的显着市场。对有针对性和高效药物输送系统的需求不断增长、对促进药物输送创新的个人化医疗的日益关注以及奈米技术的众多进步是推动市场份额增长的一些主要因素。
主要市场驱动因素:慢性病盛行率的不断上升增加了对标靶治疗的需求,进而催化了市场的成长。此外,由于患者独特的基因特征需要客製化的药物管理方法,对个人化药物的需求不断增长也促进了市场的成长。
主要市场趋势:奈米技术和生物材料的许多进步促进了精确的药物传递机制,实现了控制释放和更好的生物利用度,对市场成长产生了积极影响。此外,越来越多地采用使用者友善的药物输送系统来满足老年患者的特定需求也是推动市场成长的另一个重要趋势。
地理格局:根据报告,北美在全球市场中占据最大的市场份额,因为该地区拥有强大的医疗保健基础设施、强大的研发能力以及较高的慢性病盛行率。
竞争格局:一些领先的药物输送市场公司包括 AbbVie Inc.、Amgen Inc.、AstraZeneca plc、Becton Dickinson and Company、Eli Lilly and Company、GSK plc、Johnson & Johnson、Merck KGaA、Novartis AG、Pfizer Inc. 和 Sanofi SA 等。
挑战与机会:全球药物输送市场的挑战包括监管障碍、复杂的製造流程以及持续创新的需要。药物传输市场近期的机会包括慢性病盛行率的上升、对标靶和控制药物传输系统的需求不断增长,以及奈米技术和生物製剂的进步。
标靶治疗需求不断增长
针对性治疗需求的不断成长是药物传输市场的重要动力。传统的全身给药常常导致脱靶效应和不良反应,这增加了对标靶治疗和药物传递的需求。此外,COVID-19 等各种危及生命的感染日益流行,也促使製造商推出有效的药物输送设备和技术。预计这将在未来几年对药物输送市场的成长做出重大贡献。例如,2022 年 2 月,Glenmark Pharmaceuticals Limited 在印度推出了一种名为 FabiSpray 的一氧化氮鼻喷剂,用于治疗病情进展风险较高的 COVID-19 成年患者。此外,2020年7月Frontiers发表的文章提到,治疗糖尿病需要根据药物的性质,制定适当的给药系统和完整的治疗策略。消息人士透露,药物输送装置在糖尿病治疗的各个方面都显示出巨大的潜力。它们增强了药物的稳定性,克服了生物屏障,提高了生物利用度,并充当了模拟自然胰岛素输送的智慧自动化系统,降低了低血糖的风险。
科技快速进步
药物输送设备和技术的不断进步使其更加患者友好、易于使用和准确,进一步促进了全球药物传输市场的成长。除此之外,各主要市场参与者正大力投资先进药物输送装置的开发与创新。例如,2021 年 5 月,Phillips-Medisize 推出了其 Aria Smart Autoinjector 平台,该平台开启了製药业的创新、差异化和永续性。该设备采用先进的技术,例如模组化药物传输平台,支援多种药物配方和黏度,并具有内建蓝牙,可连接智慧型手机、平板电脑和行动应用程式。同样,2021 年 6 月,罗氏开发了一种带有雷珠单抗 (PDS)(一种药物输送植入物)的港口输送系统,使患有湿性老年黄斑部病变的患者无需频繁进行眼部注射。预计此类创新和技术进步将在未来几年推动药物输送市场收入的成长。
慢性病盛行率不断上升
世界各地各种慢性病病例的增加增加了对药品的需求。根据世界卫生组织(WHO)的数据,慢性病是全球最大的死亡原因。光是缺血性心臟病一项,在2019年就造成了约889万人死亡。此外,全球癌症、呼吸系统疾病和糖尿病患者的发生率不断上升,进一步推动了药物输送装置的普及。根据国际癌症研究机构2020年发布的资料,全球每5人中就有1人在其一生中患有癌症,每8名男性中就有1人、每11名女性中就有1人死于癌症。乳癌、大肠癌、肺癌、子宫颈癌和甲状腺癌在女性中很常见。而肺癌和摄护腺癌在男性中最为常见,占所有男性癌症的近三分之一。此外,根据印度国立卫生研究院发布的《2022年慢性病盛行率和潜在决定因素》报告,印度约有21%的老年人口患有至少一种慢性病。预计慢性病病例的增加将增加药品输送市场的需求。
The global pharmaceutical drug delivery market size was valued at USD 1,465.2 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 2,205.5 Billion by 2033, exhibiting a CAGR of 4.6% during 2025-2033. North America currently dominates the market, holding a significant market share of 42.6% in 2024. The rising demand for targeted and efficient drug delivery systems, increasing focus on personalized medicine fostering drug delivery innovations, and numerous advancements in nanotechnology are some of the major factors propelling the market share.
Major Market Drivers: The increasing prevalence of chronic diseases is augmenting the demand for targeted therapies, which in turn is catalyzing the market growth. Furthermore, the rising need for personalized medication as unique genetic profiles of patients require tailored drug administration methods is also contributing to the market growth.
Key Market Trends: Numerous advancements in nanotechnology and biomaterials that facilitate precise drug delivery mechanisms, allowing for controlled release and better bioavailability, are positively influencing market growth. Moreover, the rising adoption of user-friendly drug delivery systems that can cater to the specific needs of elderly patients is also acting as another significant trend, driving the market growth.
Geographical Landscape: According to the report, North America accounted for the largest market share in the global market since the region has a robust healthcare infrastructure, strong research and development (R&D) capabilities, and a high prevalence of chronic diseases.
Competitive Landscape: Some of the leading pharmaceutical drug delivery market companies are AbbVie Inc., Amgen Inc., AstraZeneca plc, Becton Dickinson and Company, Eli Lilly and Company, GSK plc, Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer Inc., and Sanofi S.A., among many others.
Challenges and Opportunities: Challenges in the global pharmaceutical drug delivery market include regulatory hurdles, complex manufacturing processes, and the need for continuous innovation. Pharmaceutical drug delivery market recent opportunities include increasing prevalence of chronic diseases, growing demand for targeted and controlled drug delivery systems, and advancements in nanotechnology and biologics.
Rising Demand for Targeted Therapies
The escalating demand for targeted therapies is a significant driver in the pharmaceutical drug delivery market. Traditional systemic drug administration often results in off-target effects and adverse reactions, which augment the need for targeted therapies and drug deliveries. Moreover, the growing prevalence of various life-threatening infections, such as COVID-19, is also prompting manufacturers to introduce effective drug-delivery devices and techniques. This is anticipated to significantly contribute to the pharmaceutical drug delivery market growth in the coming years. For instance, in February 2022, Glenmark Pharmaceuticals Limited launched a nitric oxide nasal spray called FabiSpray in India for the treatment of adult patients with COVID-19 who had a high risk of progression of the disease. Besides this, the article published by Frontiers in July 2020 mentioned that it is necessary to develop appropriate delivery systems and complete therapy strategies according to the nature of drugs in treating diabetes mellitus. As per the source, drug-delivery devices have shown significant potential in various aspects of diabetes treatment. They enhance the stability of drugs, overcome biological barriers to increase bioavailability, and act as a smart, automated system to mimic natural insulin delivery, reducing the risk of hypoglycemia.
Rapid Technological Advancements
Ongoing technological advancements in drug delivery devices and techniques to make them more patient-friendly, accessible, and accurate are further catalyzing the growth of the global pharmaceutical drug delivery market. In addition to this, various key market players are extensively investing in the development and innovation of advanced drug-delivery devices. For instance, in May 2021, Phillips-Medisize launched its Aria Smart Autoinjector platform, which unlocked innovation, differentiation, and sustainability in the pharmaceutical industry. This device features advanced technologies such as a modular drug delivery platform that supports a variety of drug formulations and viscosities and has built-in Bluetooth, which enables connectivity to smartphones, tablets, and mobile apps. Similarly, in June 2021, Roche developed a Port Delivery System with ranibizumab (PDS), a drug delivery implant, to free patients with wet age-related macular degeneration from the need to undergo frequent eye injections. Such innovations and technological advancements are anticipated to propel the pharmaceutical drug delivery market revenue in the coming years.
Increasing Prevalence of Chronic Diseases
The rising cases of various chronic ailments across the world are augmenting the demand for medicines and drugs. According to the World Health Organization (WHO), chronic diseases are the leading cause of death worldwide. Ischemic heart disease alone was responsible for about 8.89 million deaths in 2019. Moreover, the increasing prevalence of cancer, respiratory disease, and diabetic patients across the world is further promoting the adoption of drug delivery devices. According to the data published by the International Agency for Research on Cancer 2020, globally, 1 in 5 people develop cancer during their lifetime, and 1 in 8 men and 1 in 11 women die. Breast, colorectal, lung, cervical, and thyroid cancers are common among women. Whereas lung and prostate cancer are the most common among men, accounting for nearly one-third of all male cancers. Furthermore, according to a report published by the National Institute of Health, India, on Prevalence and Potential Determinants of Chronic Diseases, 2022, about 21% of the elderly population in India reportedly have at least one chronic disease. The escalating cases of chronic ailments are projected to bolster the pharmaceutical drug delivery market demand.
Oral drug delivery represents the most popular route of administration
Pharmaceutical drug delivery market forecast indicates that oral drug delivery is a prominent route of administration where pharmaceutical compounds are ingested through the mouth and absorbed in the gastrointestinal tract. Oral medications are convenient to administer, making it a preferred choice for various medications. Moreover, the rise in R&D activities and product launches are likely to positively impact the pharmaceutical drug delivery market outlook. For instance, in June 2021, Shilpa Medicare Ltd. launched Molshil, a pediatric dose of paracetamol oral thin film, in India. Furthermore, according to the WHO, in 2021, approximately 275 million people used medications (drugs) at least once. Among them, approximately 62 million people used opioids.
Infectious diseases account for the majority of the market share
Infectious diseases are illnesses caused by pathogenic microorganisms, such as bacteria, viruses, fungi, and parasites, which can spread from person to person or through contaminated objects. As per the pharmaceutical drug delivery market report by IMARC, the rising prevalence of infectious diseases poses significant global health challenges, necessitating effective treatment strategies. For instance, according to an article by Frontiers in February 2022, non-typhoidal Salmonella, a common cause of bacterial enteritis in humans, causes almost 93.8 million cases of gastroenteritis globally each year.
As per the pharmaceutical drug delivery market overview by IMARC, hospitals hold a significant share in the global market. Hospitals as primary care providers utilize a variety of drug delivery methods to ensure effective treatment for diverse patient needs. Ambulatory Surgery Centers demand specialized drug delivery techniques for perioperative care and pain management. Home Care Settings require user-friendly delivery systems for patient self-administration, promoting adherence and comfort. Diagnostic Centers rely on targeted drug delivery to enhance imaging and therapeutic interventions.
North America exhibits a clear dominance in the market
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
As per the pharmaceutical drug delivery market statistics by IMARC, North America held the biggest share in the market since the region has a robust healthcare infrastructure, strong research and development (R&D) capabilities, and a high prevalence of chronic diseases. For instance, according to the American Cancer Society's 2022 report, approximately 1.9 million new cancer cases were diagnosed in 2022 in the United States. Besides this, the presence of leading manufacturers in the region, along with the introduction of new products, is also bolstering the growth of the market in North America. For instance, in February 2022, the United States FDA approved the generic Apokyn (apomorphine hydrochloride injection) drug cartridges to treat hypomobility and other episodes associated with advanced Parkinson's disease.
The market research report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
Pharmaceutical Drug Delivery Market Recent Developments
January 2024: Berry Global Healthcare, a patient-centered package design company, showcased its latest range of standard and bespoke pharmaceutical packaging solutions at Pharmapack 2024. The exhibition witnessed the launch of the BerryHaler, an all-plastic, dual chamber, dry powder inhaler (DPI) designed to deliver combination drugs and separately store two medications for subsequent simultaneous inhalation.
October 2023: Victrex plc, a pioneer in the development of PEEK biomaterial solutions launched a new product grade developed exclusively for Drug Delivery and Pharmaceutical Contact applications. VICTREX PC101 meets the highest levels of Industry biocompatibility certification for USP Class VI and also meets industry standards such as USP 661 for use in non-implantable pharmaceutical contact applications.
July 2023: Viatris Inc., a global healthcare company, and Kindeva Drug Delivery L.P. announced the launch of Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the first generic version of AstraZeneca's Symbicort. It comes with an Abbreviated New Drug Application (ANDA) and is approved by the U.S. Food and Drug Administration (FDA).